



**Valiant Laboratories**  
Limited  
ESTD. 1990

January 13, 2025

To,  
Listing/Compliance Department  
BSE LTD  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001

BSE CODE - 543998

To,  
Listing/Compliance Department  
National Stock Exchange of India Limited  
"Exchange Plaza", Plot No. C/1,  
G Block Bandra-Kurla Complex,  
Bandra (E), Mumbai - 400051

NSE Symbol: VALIANTLAB

Dear Sir/Madam,

**Sub: Compliance of circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 issued by Securities and Exchange Board of India (SEBI) dated December 31, 2024.**

In compliance with Regulations 13(3), 27(2), and 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, we are attaching herewith a Quarterly Integrated Filing (Governance) Report for the quarter ended December 31, 2024 in the prescribed format.

Kindly take the same on your record.

Thanking You,

Yours Faithfully,

For **Valiant Laboratories Limited**

**Prajakta Patil**  
Company Secretary  
ICSI M. No.- A53370

[www.valiantlabs.in](http://www.valiantlabs.in) | CIN : L24299MH2021PLC365904

Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080.  
T: 022-49712001 / 49717220 / 49717221 | E: [investor@valiantlabs.in](mailto:investor@valiantlabs.in)



## FORMAT FOR QUARTERLY INTEGRATED FILING (GOVERNANCE)

A. Compliance Report on Corporate Governance to be submitted by a listed entity on a quarterly basis:

1. Name of the Listed Entity:
2. Quarter ending: December 31, 2024

<b>I. Composition of Board of Directors</b>												
<b>Title (Mr / Ms)</b>	<b>Name of the Director</b>	<b>PAN &amp; DIN</b>	<b>Category (Chairperson /Executive/Non Executive/independent/ Nominee) &amp;</b>	<b>Initial Date of appointment</b>	<b>Date of Re-appointment</b>	<b>Date of Cessation</b>	<b>Tenure</b>	<b>Date of Birth</b>	<b>No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)</b>	<b>No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) &amp; 17A(2)]</b>	<b>Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)</b>	<b>No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)</b>
Mr	Mulesh Manilal Savla	07474847	Non-Executive - Independent Director – Chairperson	14-05-2024	08-08-2024		4.16	12-10-1964	3	3	6	5
Mr	Paresh Shashikant Shah	08291953	Executive Director	16-08-2021	16-08-2021			07-05-1960	1	0	0	0
Mr	Santosh Shantilal Vora	07633923	Executive Director	16-08-2021	21-02-2022			25-07-1994	2	0	1	0
Mr	Shantilal Shivji Vora	07633852	Non-Executive - Non Independent Director	16-08-2021	21-02-2022			05-11-1952	1	0	1	0
Mrs	Sonal Amit Vira	09505883	Non-Executive - Independent Director	16-02-2022	21-02-2022		34.14	20-10-1982	2	2	3	0



**Valiant Laboratories**  
Limited  
ESTD. 1980

Mr	Sandeep Gupta	09245060	Non-Executive - Non Independent Director	23-02-2023	13-09-2023			08-12-1970	1	0	0	0
Mr	Velji Karamashi Gogri	02714758	Non-Executive - Independent Director	06-02-2022	21-02-2022	12-11-2024	33.05	14-10-1951	1	1	0	0
Mr	Ashok Lakhamshi Chheda	10776571	Non-Executive - Independent Director	12-11-2024	19-12-2024		1.19	05-07-1975	1	1	0	0
Whether the listed entity has a Regular Chairperson											Yes	
Whether Chairperson is related to MD or CEO											No	

## II. Composition of Committees

Name of Committee	Whether Regular chairperson appointed	Name of Committee Members	Category (Chairperson/Executive/Non-Executive/independent/ Nominee)	Date of Appointment	Date of Cessation
1. Audit Committee	Yes	Mulesh Manilal Savla Sonal Amit Vira Shantilal Shivji Vora	Chairperson - Non-Executive - Independent Director Member - Non-Executive - Independent Director Member - Non-Executive – Non Independent Director	12-08-2024 16-02-2022 16-02-2022	-
2. Nomination & Remuneration Committee	Yes	Sonal Amit Vira Shantilal Shivji Vora Mulesh Manilal Savla	Chairperson - Non-Executive - Independent Director Member - Non-Executive – Non Independent Director Member - Non-Executive - Independent Director	16-02-2022 16-02-2022 12-08-2024	-
3. Risk Management Committee (if applicable)		NA			
4. Stakeholders Relationship Committee	Yes	Mulesh Manilal Savla Sonal Amit Vira Santosh Shantilal Vora	Chairperson - Non-Executive - Independent Director Member - Non-Executive - Independent Director Executive Director	12-08-2024 16-02-2022 16-02-2022	-
5. Corporate Social Responsibility	Yes	Mulesh Manilal Savla Paresh Shashikant Shah Shantilal Shivji Vora	Chairperson - Non-Executive - Independent Director Executive Director Member - Non-Executive – Non Independent Director	12-08-2024 16-02-2022 16-02-2022	-



**Valiant Laboratories**  
Limited  
ESTD. 1980

### III. Meeting of Board of Directors

Date(s) of meeting (if any) in the previous quarter	Whether requirement of Quorum met (Yes/No)	Number of Directors Present	Number of Independent Directors present*	Date(s) of Meeting in the previous quarter	Maximum gap between any two consecutive meetings (in number of days)
12-11-2024	Yes	7	3	12-08-2024	91

### IV. Meeting of Committees

Name of Committee	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (Yes/No)	Number of Directors Present	No. of Independent Directors Present	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings in number of days**
Audit Committee	12-11-2024	Yes	3	2	12-08-2024	91
Nomination of Remuneration Committee	12-11-2024	Yes	3	2	-	-

### V. Affirmations

1. The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. **Yes**
2. The composition of the following committees is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015
  - a. Audit Committee **Yes**
  - b. Nomination & remuneration committee **Yes**
  - c. Stakeholders relationship committee **Yes**
  - d. Risk management committee (applicable to the top 1000 listed entities, voluntary for entities ranked 1001 to 2000) **NA**
3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. **Yes**



**Valiant Laboratories**  
Limited  
ESTD. 1980

4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. **Yes**
5. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Any comments/observations/advice of Board of Directors may be mentioned here: **Yes**

Name of signatory	Prajakta Patil
Designation	Company Secretary & Compliance Officer

**Note:**

Information at Table I and II above need to be necessarily given in 1st quarter of each financial year. However, if there is no change of information in subsequent quarter(s) of that financial year, this information may not be given by the listed entity and instead a statement “same as previous quarter” may be given.

**B. INVESTOR GRIEVANCE REDRESSAL REPORT**

<b>Investor Grievance Redressal Report</b>	
No. of investor complaints pending at the beginning of Quarter	NIL
No. of investor complaints received during the Quarter	NIL
No. of investor complaints disposed off during the Quarter	NIL
No. of investor complaints those remaining unresolved at the end of the Quarter	NIL

**C. DISCLOSURE OF ACQUISITION OF SHARES OR VOTING RIGHTS IN UNLISTED COMPANIES**

The details of acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III are given below:

<b>Sr. No.</b>	<b>Name of the unlisted company in which shares or voting rights have been acquired</b>	<b>Date of acquisition</b>	<b>Aggregate holding (% shares or voting rights) as at the end of the previous quarter</b>	<b>% shares or voting rights acquired during the quarter</b>	<b>Aggregate holding (% shares or voting rights) as at the end of the quarter</b>
NA					



**Valiant Laboratories**  
Limited  
ESTD. 1980

**D. DISCLOSURE OF IMPOSITION OF FINE OR PENALTY**

The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:

<b>S No.</b>	<b>Name of the authority</b>	<b>Nature and details of the action(s) taken or order(s) passed</b>	<b>Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority</b>	<b>Details of the violation(s)/ contravention(s) committed or alleged to be committed</b>	<b>Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible</b>
1.	Judicial Magistrate First Class	Fine of Rs. 30,000/- was imposed on the occupier of the Factory	September 30, 2024	Contravention of Rule 7-A(2)(a) of Maharashtra Factories Rules, 1963	No Impact

**E. DISCLOSURE OF UPDATES TO ONGOING TAX LITIGATIONS OR DISPUTES**

The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:

<b>S No.</b>	<b>Name of the opposing party</b>	<b>Date of initiation of the litigation / dispute</b>	<b>Status of the litigation / dispute as per last disclosure</b>	<b>Current status of the litigation / dispute</b>
NA				

\*\*\*\*\*